Can GlaxoSmithKline plc & Royal Dutch Shell Plc’s Sky-High Yields Survive 2016?

2015 has been a tough year for income giants GlaxoSmithKline plc (LON: GSK) and Royal Dutch Shell Plc (LON: RDSB). Harvey Jones asks: can the yield survive?

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

sdf

The FTSE 100 is packed with mind-boggling yields right now, although it boggles the mind how long many can last. Be warned, the higher they go, the riskier they become.

Glaxo Didn’t Go

This time last year I tipped pharmaceutical giant GlaxoSmithKline (LSE: GSK) as one of my favourites for 2015, but how wrong I was. It is down nearly 10% over the last 12 months. Clearly, I failed to understand just how deep-rooted its problems are. It remains too dependent on its respiratory treatment, Advair, a former money-spinner that is now facing pricing pressures in the US and Europe, while its pipeline of 40 new drugs and vaccines in Phase II/III clinical development isn’t ready to pick up the slack as yet. Earnings per share (EPS) fell 13% in Q3, although this largely reflects dilution from the Novartis transaction.

Promises, Promises

All is not lost. Glaxo’s gGroup Q3 sales rose 11%, with its pharmaceuticals, vaccines and consumer healthcare divisions all holding their own. This should help underpin management’s commitment to paying an annual ordinary dividend of 80p for the three years running to 2017. Today’s 6.1% yield of 6.1% is covered just 1.2 times, so Glaxo will need the cash to keep flowing to meet its commitment.

EPS should recover next year, with a forecast rise of 11% to 84.33p. Revenues may stagnate but pre-tax profits are forecast to rise from around £5.1bn this year to £5.74 next year, which suggests that management should be able to maintain its payout, especially given the embarrassment of failing to meet its recent firm promise.

Not So Sure Of Shell

I may have bigged up Glaxo last year but at least I had the sense to dump my holdings in Royal Dutch Shell (LSE: RDSB), which is down a whopping 28% over the past 12 months. Naturally, the plummeting oil price is mostly to blame, and with Saudi Arabia dashing hopes that it would cut production at the recent Opec meeting, it could fall further still.

This is really turning up the heat on Shell, which currently yields 7.1%. Cover for the payout is forecast to fall to just one times, putting it under real pressure. Shell has never cut dividends since the war, but we live in turbulent times, and that proud record could fall next year.

Troubled Waters

Nerves will be frazzled, especially with Shell slumping to a third quarter loss of $6.1bn, well short of forecasts, due to write-offs and lower oil and gas prices. Both net investments and dividend payments were covered from cash flow, however, and is management is keen to point out, the merger with BG Group should boost cash flows.

The yield is supported for now and cost cutting should help Shell buy time. Most of its recent losses were down to writing off projects that weren’t actually producing any oil. It can withstand oil prices for a while, but unless the price picks up in the second half of next year, it may run into trouble: $11.6bn a year is a lot of money.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Harvey Jones has no position in any shares mentioned. The Motley Fool UK has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investor looking at stock graph on a tablet with their finger hovering over the Buy button
Investing Articles

Could the stock market crash in the second half of 2025?

As the FTSE 100 hits a new high, could a stock market crash be coming? Our writer thinks there's a…

Read more »

Man hanging in the balance over a log at seaside in Scotland
Investing Articles

Start investing this summer with a spare £250? Here’s how!

Christopher Ruane explains how an investor with a few hundred pounds to spare and no prior experience could look to…

Read more »

Young female analyst working at her desk in the office
Investing Articles

Is Palantir stock the new Nvidia? Why UK investors should (or shouldn’t) care

Palantir stock’s the top performer on the S&P 500 this year. Should UK investors consider it amid a blistering AI-fuelled…

Read more »

Investing Articles

3 FTSE 100 shares I think look undervalued

The FTSE 100 may be hitting record highs but there are still bargains to be had on the index. I…

Read more »

Close-up image depicting a woman in her 70s taking British bank notes from her colourful leather wallet.
Investing Articles

£20,000 in savings? Here’s how to target £841 of passive income each month

Passive income plans don't need to be complicated. Our writer explains how someone could target a sizeable second income buying…

Read more »

Happy couple showing relief at news
Investing Articles

3 passive income strategies I like to try to double the State Pension with just £100 a month

Investing consistently, with diligence, and patience can lead to an impressive stock market income that puts the State Pension to…

Read more »

ISA Individual Savings Account
Investing Articles

£20,000 invested in a Stocks and Shares ISA 10 years ago could now be worth…

Stocks and Shares ISA investors have earned tremendous returns in the last decade, but just how much money has been…

Read more »

British coins and bank notes scattered on a surface
Investing Articles

An 11.5% yield?! Here’s the dividend forecast for a hot income stock

This steadily recovering income stock has the highest dividend yield in the FTSE 250, which looks like it’s here to…

Read more »